Objective. Evaluate the impact of cervical metastasis on the survival of patients with squamous cell carcinoma (SCC) of the hard palate. Methods. 155 cases of SCC of the hard palate hospitalized in Cancer Center, Sun Yat-sen University, from 1964 to 2008 were reviewed retrospectively. Results. The 5-year DSS rates for Nþ and N0 patients were 21.54% and 47.36% (P ¼ .048). The 5-year DSS rates were 47.36%, 27.48%, 15.55% and 0 for N0-N3 lesions, respectively (P ¼ .041). Cervical metastasis was detected in 40% patients for initial consultation. After therapy, those individuals who presented with clinically negative necks had a 9.03% rate of cervical metastasis. Ultimately, 49.03% of patients manifested disease to the cervical lymph nodes. Conclusion. The presence of cervical nodal disease in patients is associated with the decreased survival rates. SCC of the hard palate should be treated aggressively, and elective neck dissection should be considered because of the high rate of cervical metastasis. (Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:23-27) Squamous cell carcinoma, the most common malignancy of the oral cavcity, has a predilection for regional lymphatic metastasis. These tumors metastasize, usually through the lymphatic system to cervical lymph nodes in levels I and II.
Squamous cell carcinoma, the most common malignancy of the oral cavcity, has a predilection for regional lymphatic metastasis. These tumors metastasize, usually through the lymphatic system to cervical lymph nodes in levels I and II. 1, 2 Several studies have been done on the metastasis of squamous cell carcinoma of the tongue and floor of mouth. 3 Only a few studies have been performed concerning metastasis of squamous cell carcinoma of the hard palate. [4] [5] [6] [7] There is often a mixture of sites with these studies including tumors of the soft palate, alveolus and/or cheek. This mixture of tumor sites makes the evaluation of the impact of cervical metastasis on the survival of patients with squamous cell carcinoma of the hard palate more difficult and those studies looking exclusively at squamous cell carcinoma of the hard palate are usually small. But it is striking that the incidence of cervical lymph node metastasis from cancer of the hard palate is significant. Therefore, we report only patients with a cancer confined to the hard palate and only squamous cell carcinoma in an effort to specifically evaluate the risk of regional metastasis from the hard palate.
PATIENTS AND METHODS Patients
Between 1964 and 2008, 155 patients were treated at the Cancer Center of the Sun Yat-Sen University, for squamous cell carcinoma of the hard palate. All patients were previously untreated. Initial examination included medical history, physical examination with special emphasis on the head and neck region, routine blood tests, chest X-ray, and electrocardiogram. CT-scan and biopsy were not routinely performed for all patients. Patients with tumors extending to the hard palate from adjacent areas (e.g., tonsil, soft palate, and retromolar trigone) were excluded.
Patients and tumor characteristics are shown in Table I Of the 97 (62.58%) patients who were treated primary by surgery, palatal tumor resection was performed in 14 patients, total maxillectomy in 8, partial maxillectomy in 55, and palatectomy in 20.
Of the 62 (40%) patients who were clinically nodepositive at presentation, neck dissections were performed in 32 patients (modified radical neck dissection in 23 patients, radical neck dissection in 5 patients and elective neck dissection in 4 patients). Thirty patients were treated with radiation or chemotherapy or concurrent chemoradiation. Elective neck dissection was performed in 1 patient who was clinically node-negative at presentation and was found to be pathologically N0.
Observation of the regional lymphatics was used in the 92 patients, clinically staged as N0.
Radiotherapy was performed with photons from 60 Co or a linear accelerator (6 MV) with or without 9-12 MeV electrons. The dose of radiation (DT) ranged from 42 to 79 GY. Chemotherapy regimens included cisplatin or BPF (cisplatin, bleomycin, and 5-fluorouracil).
Follow-up
Patients were followed up regularly, every month for 3 months, every 3-6 months for 2 years and with decreasing frequency in the subsequent period. Median follow-up period was 22.03 months (range from 0 to 388.3 months). The follow-up rate was 96.77%, and data from patients lost to follow-up were censored. Follow-up evaluations were carried out with physical examination and/or imaging studies, including computed tomography, magnetic resonance imaging.
Statistical analysis
All statistical analyses of the data were performed with SPSS 13.0 computer software (SPSS Inc., Chicago, IL, USA). Survival differences according to the presence or absence of cervical nodal disease and N-stage were determined with KaplaneMeier method and the log-rank test. A P value <.05 was considered statistically significant. Disease-specific survival was defined as the date of discharge from hospital until the day of death or last follow-up.
RESULTS
Locoregional recurrence and metastatic patterns of patients are shown in Table III . Among the 44 recurrences, 22 had a local recurrence, 10 had both local and cervical lymph node recurrence (5 patients with no metastases in the neck at presentation and 5 patients with metastases in the neck at presentation), 12 had cervical lymph node recurrence (9 patients with no metastases in the neck at presentation and 3 patients with metastases in the neck at presentation). RT, radiotherapy; CT, chemotherapy; CRT, chemoradiation therapy.
The total recurrence rate was 28.39% (44/155), and the median time to recurrence was 7.9 months (range, 0.67-322.93 months). Fourteen of the 44 patients with recurrence received surgery alone, 6 received surgery plus postoperative radiotherapy, 1 received surgery plus postoperative chemotherapy, 11 received chemotherapy alone, 2 received radiotherapy alone, and 10 patients were given palliative treatment.
Five (3.23%) patients had distant metastasis and the median time to metastasis was 20.53 months. Four patients had lung metastasis, 1 had liver metastasis. All patients were given palliative treatment and all died of disease at 18.73 months from recurrence (range, 1.57-45.3 months).
Cervical metastasis was detected in 40% (62 cases) of those individuals with hard palate squamous cell carcinoma presenting for initial consultation (stageT1: 45.45%; T2: 35.59%; T3: 50%; T4: 40%), as evidenced by either clinical examination or radiographic findings consistent with malignancy. On average, 9.03% (14 cases) of the patients with clinically and radiographically negative necks at the time of presentation went on to develop cervical disease 11.83 months after therapy. Ultimately, 49.03% (76 cases) of our patients manifested disease to the cervical lymph nodes. Primary tumor 2 cm or less in the greatest dimension in 21 patients, primary tumor more than 2 cm but not more than 4 cm in the greatest dimension in 38 patients, and primary tumor more than 4 cm in 17 patients. The presence of nodal disease significantly impacted mean (64.16 vs. 136.31 months), median (22.03 vs. 50.07 months), and 5-year disease-specific (21.54% vs. 47.36%) survival times when compared to N0 patients (P ¼ .048). The KaplaneMeier disease-specific survival curves for patients with and without nodal disease are shown in Figure 1 . With regard to N-stage, the 5-year disease-specific survival rates were 47.36%, 27.48%, 15.55%, and 0 for N0-N3 lesions, respectively (P ¼ .041). Figure 2 displays KaplaneMeier diseasespecific survival curves for these nodal stages.
A literature search returned 4 reports addressing the cervical lymph node status of patients with maxillary gingival, alveolus and palate squamous cell carcinoma. The patients reported by Simental et al., 5 Mourouzis et al., 8 and Montes et al. 7 reported patients with squamous cell carcinoma of the maxillary gingival, alveolus, and palate treated primarily by surgery. Yorozu et al. 9 reviewed 17 patients with the hard palate squamous cell carcinoma with an N0 neck who received radiation treatment limited to the primary tumor in an N0 neck. Table IV summarizes the nodal status at presentation, clinical failure rates, and therapeutic modalities for these 4 study groups.
DISCUSSION
In our experience, the presence of nodal disease significantly impacted mean (64.16 vs. 136.31 months), median (22.03 vs. 50.07 months), and 5-year disease-specific (21.54% vs. 47.36%) survival times when compared to N0 patients (P ¼ .048). The 5-year disease-specific survival rates were 47.36%, 27.48%, 15.55%, and 0 for N0-N3 lesions, respectively (P ¼ .041). Presence of lymph node metastases is a high-malignancy index, with a subsequently very negative prognosis and advanced N-stage significantly correlate with worse prognosis.
A high incidence of cervical metastasis (30%) observed in the sites of tongue and floor of mouth cancer has been well documented. 2, 10, 11 There are little data specifically reporting on cervical metastasis from squamous cell carcinoma arising on the hard palate. We found cervical metastasis from squamous cell carcinoma of the hard palate in 40% (62/155) patients. This rate is much higher than expected. A review of the current literature shows that at initial presentation, maxillary palatal, gingival, and alveolar squamous cell carcinomas manifest clinically detectable cervical metastasis at rates ranging from 11.5% to 26.3% (Table IV) . 5, [7] [8] [9] This variation may be due to: 1) those studies looking exclusively at squamous cell carcinoma of the hard palate are usually small; 2) the mixture of tumor sites makes interpretation of results more difficult; 3) our study presented data concerning the proportion of the cervical metastasis only in the site of hard palate.
As for regional metastasis, we report a 9.03% (14/ 155) rate in patients who presented initially without cervical metastasis and were followed up by observation alone. The patient groups presented in Table IV had a potential for occult cervical metastasis ranging from 11.8% to 29.2%. Considering the patients presenting with cervical disease at presentation as well as regional failures in all 5 study groups, we find a cervical failure rate as high as 50%. Our study and review of the literature demonstrate that the rate of cervical metastasis from squamous cell carcinoma of the hard palate is comparable to that of those of the oral tongue, mandibular gingival, and floor of the mouth. Although squamous cell carcinomas of the hard palate replicate the high frequency of regional metastatic disease as the oral tongue and floor of the mouth, optimal management of the clinically negative neck in patients diagnosed with hard palate squamous cell carcinoma remains less clear. For squamous cell carcinomas of the tongue, mandibular alveolus, and floor of the mouth in N0 patients, outcomes are significantly improved after primary surgical resection with concomitant neck dissection 12, 13 based on the evidence presented herein, elective neck dissection may be offered to patients with squamous cell carcinoma of the hard palate even in cases with a negative clinical examination.
CONCLUSION
The presence of cervical nodal disease in patients is associated with the decreased survival rates. Advanced N-stage significantly correlated with the worse prognosis. Squamous cell carcinoma of the hard palate should be treated aggressively, and elective neck dissection should be considered because of the high rate of cervical metastasis.
